GlaxoSmithKline opens new global vaccines research and development centre

GlaxoSmithKline has announced the inauguration of its newest global vaccines research and development centre, which will create up to 200 new jobs.

The site in Rockville, Maryland will further strengthen and expand the company's vaccines presence in the US and will see GlaxoSmithKline spend more than $50 million (39.9 million pounds) developing the site over the next two years.

Dr Ripley Ballou will head up the staff at the new facility, which will house a total of 12 critical vaccine development programmes, including projects supporting its vaccines for shingles respiratory syncytial virus, group B streptococcus and dengue fever.

Rockville becomes one of three global vaccines research and development centres for GlaxoSmithKline, complementing its existing facilities in Rixensart, Belgium and Siena, Italy.

Luc Debruyne, president of GlaxoSmithKline's vaccines business, said: "Our investment here signifies our commitment to discovering and developing new vaccines across a range of pressing public health priorities."

The site was acquired from Human Genome Sciences in 2012 and offers proximity to current research partners such as the National Institutes of Health and PATH, as well as important public health stakeholders.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.